Gunaseelan Sushil, Prakash Anand
Department of Pediatrics, Division of Pediatric Hematology and Oncology, St. John's Medical College and Hospital, Bangalore, India.
J Pediatr Hematol Oncol. 2017 Nov;39(8):e519-e520. doi: 10.1097/MPH.0000000000000860.
β-thalassemia major is a hereditary anemia resulting from defects in β-globin production. It is also characterized by a hypercoagulable state with an increased risk of thrombosis. Thalidomide, a drug known for its immunomodulating and antiangiogenic properties, has recently been demonstrated to induce γ-globin gene expression and to increase the proliferation of erythroid cells. An increasing incidence of thromboembolic events in thalidomide-treated patients has been reported. This is often in the context of thalidomide combinations with other drugs, including steroids and particularly anthracycline-based chemotherapy, and with very low incidence of thrombosis with single-agent thalidomide treatment. We report a case of stroke in a β-thalassemic child who had received a course of thalidomide.
重型β地中海贫血是一种由β珠蛋白生成缺陷导致的遗传性贫血。它还具有高凝状态的特征，血栓形成风险增加。沙利度胺是一种以免疫调节和抗血管生成特性而闻名的药物，最近已被证明可诱导γ珠蛋白基因表达并增加红系细胞的增殖。据报道，接受沙利度胺治疗的患者血栓栓塞事件的发生率不断增加。这通常发生在沙利度胺与其他药物联合使用的情况下，包括类固醇，尤其是基于蒽环类药物的化疗，而单药沙利度胺治疗的血栓形成发生率非常低。我们报告了一例接受过沙利度胺疗程的β地中海贫血儿童发生中风的病例。
